Literature DB >> 30527556

Observational studies with type 2 diabetes mellitus treatments in Spain: A systematic literature review.

Silvia Díaz1, Tatiana Dilla2, Jesus Reviriego2.   

Abstract

The aim of this systematic literature review (SLR) was to provide an overview of the Spanish research landscape of observational studies conducted with antidiabetic drugs in T2DM patients, published in the last five years, with special focus on the objectives, methodology and main research areas. Twenty-two articles, corresponding to 20 studies, were included in the analysis. Around 82% of the studies employed a longitudinal study design, collected data retrospectively (72.7%), and were based on secondary data use (63.6%). Pharmacotherapeutical groups most frequently studied were insulin (31.8%) and DPP4i (13.6%). Analytic design was employed most in the studies (68.2%), followed by descriptive analysis (22.7%). In the top five of the most studied variables are those related to effectiveness assessed according to glycaemic control (91%), treatment patterns (82%), safety (hypoglycaemia) (59%), the identification of effectiveness predictive factors (45%) and effectiveness according to other control measures such as anthropometric control or cardiovascular risk factors (36%).
Copyright © 2018. Publicado por Elsevier España, S.L.U.

Entities:  

Keywords:  Antidiabetic drugs; Diabetes mellitus tipo 2; España; Estudios observacionales; Fármacos antidiabéticos; Observational studies; Revisión sistemática de la literatura; Spain; Systematic literature review; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 30527556     DOI: 10.1016/j.endinu.2018.09.002

Source DB:  PubMed          Journal:  Endocrinol Diabetes Nutr (Engl Ed)        ISSN: 2530-0180            Impact factor:   1.417


  1 in total

1.  Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population.

Authors:  Itziar Oyagüez; Fernando Gómez-Peralta; Sara Artola; Francisco J Carrasco; Juana Carretero-Gómez; Javier García-Soidan; Ricardo Gómez-Huelgas; Juan F Merino-Torres; Antonio Pérez
Journal:  Diabetes Ther       Date:  2021-05-04       Impact factor: 2.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.